Long-term results of valve replacement with the CarboMedics prosthetic heart valve.
This study examined the long-term results of the CarboMedics prosthetic heart valve. Between July 1990 and May 2000, 256 CarboMedics valve prostheses (120 single aortic, 62 single mitral, and 34 double aortic/mitral) were implanted into 216 patients (mean age 57.8 years). The mean follow-up was 57.7 +/- 36 months (maximum 133 months) with a total of 1,038.4 patient years. Patient survival, including operative deaths, was 85.1% at 10 years. Linearized rates for various complications were thromboembolism 0.39% per patient year, bleeding events 0.39% per patient year; prosthetic valve endocarditis 0.29% per patient year, nonstructural dysfunction 0.87% per patient year, and reoperation 0.39% per patient year. There were no valve thrombosis or structural valve failures in this series. The probabilities of freedom from thromboembolism and reoperation at 10 years were 96.3% and 93.1%, respectively. In conclusion, the CarboMedics valve can be used satisfactorily with a low incidence of thromboembolism and valve thrombosis.